American International Group Inc. Boosts Stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

American International Group Inc. raised its position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 27.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 11,349 shares of the company’s stock after buying an additional 2,479 shares during the period. American International Group Inc.’s holdings in Tarsus Pharmaceuticals were worth $205,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BlackRock Inc. increased its stake in shares of Tarsus Pharmaceuticals by 8.6% during the 1st quarter. BlackRock Inc. now owns 1,457,260 shares of the company’s stock worth $18,318,000 after purchasing an additional 116,001 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Tarsus Pharmaceuticals by 42.7% during the 3rd quarter. Vanguard Group Inc. now owns 935,649 shares of the company’s stock worth $16,018,000 after purchasing an additional 279,826 shares during the last quarter. State Street Corp increased its stake in shares of Tarsus Pharmaceuticals by 5.1% during the 1st quarter. State Street Corp now owns 364,295 shares of the company’s stock worth $4,579,000 after purchasing an additional 17,635 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Tarsus Pharmaceuticals by 2.3% during the 1st quarter. Geode Capital Management LLC now owns 349,149 shares of the company’s stock worth $4,389,000 after purchasing an additional 7,958 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Tarsus Pharmaceuticals by 18.0% during the 1st quarter. Dimensional Fund Advisors LP now owns 235,530 shares of the company’s stock worth $2,961,000 after purchasing an additional 35,854 shares during the last quarter. Hedge funds and other institutional investors own 70.02% of the company’s stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 8,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $17.23, for a total value of $137,840.00. Following the completion of the transaction, the chief executive officer now directly owns 902,106 shares of the company’s stock, valued at approximately $15,543,286.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Tarsus Pharmaceuticals news, CEO Bobak R. Azamian sold 8,000 shares of the firm’s stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $17.23, for a total value of $137,840.00. Following the completion of the transaction, the chief executive officer now directly owns 902,106 shares of the company’s stock, valued at approximately $15,543,286.38. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Jose M. Trevejo sold 1,604 shares of the firm’s stock in a transaction on Thursday, October 5th. The shares were sold at an average price of $18.00, for a total transaction of $28,872.00. Following the completion of the transaction, the insider now directly owns 4,503 shares of the company’s stock, valued at $81,054. The disclosure for this sale can be found here. Insiders sold a total of 25,604 shares of company stock valued at $410,312 in the last three months. Company insiders own 11.54% of the company’s stock.

Tarsus Pharmaceuticals Stock Down 7.2 %

Shares of NASDAQ:TARS opened at $17.50 on Tuesday. The firm has a fifty day moving average price of $15.81 and a two-hundred day moving average price of $17.03. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.15 and a quick ratio of 12.43. Tarsus Pharmaceuticals, Inc. has a one year low of $11.33 and a one year high of $25.25. The company has a market cap of $579.34 million, a price-to-earnings ratio of -4.58 and a beta of 0.79.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on TARS shares. The Goldman Sachs Group started coverage on shares of Tarsus Pharmaceuticals in a research note on Monday. They set a “neutral” rating and a $19.00 price target for the company. Bank of America raised their price objective on shares of Tarsus Pharmaceuticals from $42.00 to $54.00 in a report on Wednesday, July 26th. HC Wainwright raised their price objective on shares of Tarsus Pharmaceuticals from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, November 10th. Finally, Guggenheim raised their price objective on shares of Tarsus Pharmaceuticals from $46.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, September 11th.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.